UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $8.87 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 532.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 165,737 shares of the company's stock after purchasing an additional 139,543 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.32% of Janux Therapeutics worth $8,874,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JANX. RA Capital Management L.P. lifted its position in Janux Therapeutics by 13.1% during the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after buying an additional 1,200,000 shares during the period. Paradigm Biocapital Advisors LP grew its holdings in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after purchasing an additional 1,115,412 shares during the period. Janus Henderson Group PLC grew its stake in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after buying an additional 1,038,996 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after buying an additional 986,750 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Janux Therapeutics by 596.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock valued at $59,429,000 after buying an additional 950,557 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,464,170. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10% increase in their position. The disclosure for this purchase can be found here. Insiders own 8.10% of the company's stock.

Janux Therapeutics Price Performance

Shares of JANX traded down $0.30 during midday trading on Wednesday, reaching $25.13. The stock had a trading volume of 543,953 shares, compared to its average volume of 873,370. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The firm's 50 day moving average price is $27.10 and its 200-day moving average price is $38.15. The company has a market capitalization of $1.49 billion, a P/E ratio of -21.48 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JANX. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Wedbush reissued an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.